Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,385
  • Shares Outstanding, K 63,706
  • Annual Sales, $ 200 K
  • Annual Income, $ -28,960 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta -0.36
  • Price/Sales 66.77
  • Price/Cash Flow N/A
  • Price/Book 4.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.06 on 11/14/24
  • Next Earnings Date 11/15/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1628 +30.84%
on 11/19/24
0.2749 -22.52%
on 11/04/24
-0.0541 (-20.25%)
since 10/25/24
3-Month
0.1628 +30.84%
on 11/19/24
0.3900 -45.38%
on 08/26/24
-0.1566 (-42.37%)
since 08/23/24
52-Week
0.1628 +30.84%
on 11/19/24
0.6200 -65.65%
on 04/11/24
-0.2167 (-50.43%)
since 11/24/23

Most Recent Stories

More News
Insider Purchase: CEO & President of $AIM (AIM) Buys 85,000 Shares

Thomas K Equels, the CEO & President of $AIM ($AIM), bought 85,000 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

AIM : 0.2130 (+1.38%)
Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares

Thomas K Equels, the CEO & President of $AIM ($AIM), bought 60,110 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

AIM : 0.2130 (+1.38%)
AIM ImmunoTech Inc. Announces Publication of Promising Data from Roswell Park Phase 1 Study on Ampligen® for Early-Stage Triple-Negative Breast Cancer

AIM ImmunoTech announces promising Phase 1 trial results for Ampligen® in early-stage triple-negative breast cancer.Quiver AI SummaryAIM ImmunoTech Inc. announced the publication of promising data from...

AIM : 0.2130 (+1.38%)
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

AIM : 0.2130 (+1.38%)
AIM ImmunoTech Inc. Reports Progress in Ampligen® Clinical Development for Pancreatic Cancer and Other High-Need Indications

AIM ImmunoTech reports progress on Ampligen® trials, particularly in pancreatic cancer, and hosts a conference call today.Quiver AI SummaryAIM ImmunoTech Inc. has announced continued progress in its clinical...

AIM : 0.2130 (+1.38%)
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM : 0.2130 (+1.38%)
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

AIM : 0.2130 (+1.38%)
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

AIM : 0.2130 (+1.38%)
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM : 0.2130 (+1.38%)
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer

USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase...

NVS : 103.54 (-0.71%)
ONCY : 0.9350 (-2.00%)
ONC.TO : 1.31 (-1.50%)
RHHBY : 35.6200 (+0.51%)
BMEA : 6.93 (+7.61%)
AIM : 0.2130 (+1.38%)
AZN : 66.40 (+1.17%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.2340
2nd Resistance Point 0.2295
1st Resistance Point 0.2212
Last Price 0.2130
1st Support Level 0.2084
2nd Support Level 0.2039
3rd Support Level 0.1956

See More

52-Week High 0.6200
Fibonacci 61.8% 0.4453
Fibonacci 50% 0.3914
Fibonacci 38.2% 0.3375
Last Price 0.2130
52-Week Low 0.1628

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar